OXYLIPINS FROM STEARIDONIC ACID AND GAMMA-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUF A)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.
1 . An isolated dihydroxy or trihydroxy oxylipin of stearidonic acid (SDA).
2 . The isolated oxylipin of claim 1 , wherein the oxylipin is an R- or S-epimer or an R/S epimer of 6,13-dihydroxy SDA or 6,16-dihydroxy SDA, or an analog, derivative or salt thereof.
3 . An isolated monohydroxy oxylipin of stearidonic acid (SDA), wherein the oxylipin is an R- or S-epimer of an oxylipin selected from the group consisting of: 6-hydroxy SDA, 7-hydroxy SDA, 10-hydroxy SDA, 12-hydroxy SDA, 15-hydroxy SDA and 16-hydroxy SDA or an analog, derivative or salt thereof.
4 . (canceled)
5 . The composition of claim 4 , further comprising a compound selected from the group consisting of: SDA, GLA, DPAn-6, DPAn-3, DTAn-6, DHA, EPA, an oxylipin derivative of GLA, an oxylipin derivative of DPAn-6, an oxylipin derivative of DPAn-3, an oxylipin derivative of DTAn-3, an oxylipin derivative of DHA and an oxylipin derivative of EPA.
6 . An isolated dihydroxy or trihydroxy oxylipin of γ-linolenic acid (GLA).
7 . The isolated oxylipin of claim 6 , wherein the oxylipin is an R- or S-epimer or an R/S epimer of 6,13-dihydroxy GLA, or an analog, derivative or salt thereof.
8 . An isolated monohydroxy oxylipin of γ-linolenic acid (GLA), wherein the oxylipin is an R- or S-epimer of an oxylipin selected from the group consisting of: 7-hydroxy GLA and , 12-hydroxy GLA, or an analog, derivative or salt thereof.
9 . (canceled)
10 . A composition comprising a compound selected from the group consisting of: SDA, GLA, DPAn-6, DPAn-3, DTAn-6, DHA, EPA, an oxylipin derivative of SDA, an oxylipin derivative of GLA, an oxylipin derivative of DPAn-6, an oxylipin derivative of DPAn-3, an oxylipin derivative of DTAn-3, an oxylipin derivative of DHA and an oxylipin derivative of EPA.
11 - 14 . (canceled)
15 . An oil comprising at least about 10 μg of at least one oxylipin per gram of oil, wherein the oxylipin is selected from the group consisting of an oxylipin from SDA and an oxylipin from GLA.
16 - 23 . (canceled)
24 . The oil of claim 15 , wherein the oxylipin is an R- or S-epimer of an oxylipin selected from the group consisting of: 6-hydroxy SDA, 7-hydroxy SDA, 9-hydroxy SDA, 10-hydroxy SDA, 12-hydroxy SDA, 15-hydroxy SDA, 16-hydroxy SDA, 6,13-dihydroxy SDA, and 6,16-dihydroxy SDA, 6-hydroxy GLA, 7-hydroxy GLA, 9-hydroxy GLA, 12-hydroxy GLA, 13-hydroxy GLA and 6,13-dihydroxy GLA, or an analog, derivative or salt thereof.
25 - 29 . (canceled)
30 . A composition comprising a long chain polyunsaturated fatty acid (LCPUFA) selected from the group consisting of: SDA and GLA, and a pharmaceutically or nutritionally acceptable carrier.
31 . The composition of claim 30 , further comprising aspirin.
32 . The composition of claim 30 , further comprising an enzyme that catalyzes the production of an oxylipin from the LCPUFA.
33 . A method to prevent or reduce at least one symptom of inflammation or neurodegeneration in an individual, comprising administering to an individual at risk of, diagnosed with, or suspected of having inflammation or neurodegeneration or a condition or disease related thereto, an agent selected from the group consisting of: an oxylipin derivative of SDA and an oxylipin derivative of GLA, to reduce at least one symptom of inflammation or neurodegeneration in the individual.
34 - 37 . (canceled)
38 . The method of claim 33 , further comprising administering at least one long chain fatty acid and/or at least one oxylipin derivative thereof to the individual.
39 - 43 . (canceled)
44 . The method of claim 33 , wherein the oxylipin derivative is selected from the group consisting of: R-epimers of the monohydroxy products of SDA, S-epimers of the monohydroxy product of SDA, R-epimers of the monohydroxy products of GLA, S-epimers of the monohydroxy product of GLA, R-epimers of the dihydroxy products of SDA, S-epimers of dihydroxy products of SDA, R-epimers of the dihydroxy products of GLA, S-epimers of dihydroxy products of GLA, R-epimers of the trihydroxy products of SDA, S-epimers of the trihydroxy products of SDA, R-epimers of the trihydroxy products of GLA, and S-epimers of the trihydroxy products of GLA.
45 - 49 . (canceled)
50 . A method to produce oxylipin derivatives of SDA or GLA, comprising chemically synthesizing an oxylipin derivative of SDA or an oxylipin derivative of GLA, wherein the oxylipin derivative is an R- or S-epimer of an oxylipin selected from the group consisting of: 6-hydroxy SDA; 7-hydroxy SDA; 9-hydroxy SDA; 10-hydroxy SDA; 12-hydroxy SDA;; 6,13-dihydroxy SDA; 6-hydroxy GLA; 7-hydroxy GLA; 9-hydroxy GLA; 12-hydroxy GLA; 13-hydroxy GLA; and 6,13-dihydroxy GLA.
51 - 53 . (canceled)
54 . A method to produce oxylipin derivatives of SDA or GLA, comprising culturing SDA- or GLA-producing microorganisms or growing SDA- or GLA-producing plants that have been genetically modified to overexpress an enzyme that catalyzes the production of the oxylipin derivatives from SDA or GLA, to produce said oxylipin derivatives.
55 - 58 . (canceled)
59 . A method to produce oxylipin derivatives of SDA or GLA, comprising contacting SDA or GLA produced by SDA- or GLA-producing microorganisms, SDA- or GLA-producing plants, or SDA- or GLA-producing animals, with an enzyme that catalyzes the conversion of said SDA or GLA to oxylipin derivatives thereof.
60 - 95 . (canceled)
96 . An organism comprising a classical fatty acid synthase pathway for the production of a long chain fatty acid selected from the group consisting of SDA and GLA, wherein the organism has been genetically transformed to express an enzyme that converts the SDA or GLA to an oxylipin.
97 - 100 . (canceled)